Vincent Rajkumar, MD · @VincentRK“We have a cure definition for myeloma. Requires: 1) Off all therapy and sustained MRD negative for 5 years 2) Negative imaging studies Presented by @NikhilMunshiMD #IMS26 @Myeloma_Society”
View post ↗Full IMS26 coverage on KOL Pulse →An IARC Perspective on Lung Cancer Screening, highlighted by Dr. Allan Pereira, notes a proven mortality reduction and positive benefit-harm balance for the practice. The perspective advocates for integrated care pathways using LDCT with smoking cessation support, while concluding chest X-rays are ineffective and AI should serve as a 'co pilot, not a replacement'.
“AI as a co pilot, not a replacement.”
— @DrAllanPereira · AI in Screening · View post ↗📌 Amplified by @KolPulseAI
“Integrated Care Pathways: LDCT with smoking cessation support”
— @DrAllanPereira · Lung Cancer Screening · View post ↗📌 Amplified by @KolPulseAI
The final analysis of the IMpassion050 trial showed adding atezolizumab in HER2+ early breast cancer did not improve pCR, EFS, or DFS. The breast oncology community is also discussing significant unmet needs in metastatic disease, particularly for new targets and therapies after progression on T-DXd in HER2+ and Trop2 ADCs in TNBC. Additionally, some physicians are advocating for carboplatin-sparing approaches in HER2+ early breast cancer, citing data suggesting a marginal therapeutic role.
“In HER2+ EBC, adding atezolizumab did not improve pCR; at ~44-mo f/u, there was also no significant EFS (HR 0.90) or DFS benefit (HR 0.71).”
— @dr_yakupergun · IMpassion050 trial results · View post ↗📌 Amplified by @KolPulseAI
“We need new targets, new payloads, new 2L and 3L options in TNBC and HeR2+ MBC!”
— @drsarahsam · Unmet needs in MBC · View post ↗📌 Amplified by @KolPulseAI
“ADC are “better chemo” but we need game changers that transform the tail of the OS curve”
— @nlinmd · Post-ADC treatment gaps · View post ↗📌 Amplified by @KolPulseAI
“One more reason to consider carboplatin-sparing approaches in HER2+ eBC, where recent data suggest marginal therapeutic role.”
— @PTarantinoMD · Carboplatin in HER2+ eBC · View post ↗The FDA approved the FGFR inhibitor lirafugratinib for previously treated patients with FGFR2-positive cholangiocarcinoma, based on the REFOCUS trial which showed a 46% overall response rate. Separately, the final 5-year analysis of the ASCOT trial in resected biliary tract cancer demonstrated adjuvant S-1 improved median overall survival to 8.2 years versus 5.9 years with observation (HR 0.72). In pancreatic cancer, new preclinical research highlighted mechanisms of liver metastasis and strategies to improve KRAS inhibition. A new trial is also activating for second-line RAS-mutant colorectal cancer, investigating FOLFIRI/bevacizumab with or without the oncolytic virus pelareorep.
“Based off REFOCUS, lirafugratinib (FGFR inhibitor) is now @FDA ✅ for FGFR2 positive cholangiocarcinoma in 2L and beyond: - ORR: 46% - mDoR: 11.8mos - AEs: Occular toxicity and hyperphosphatemia.”
— @OncBrothers · Lirafugratinib approval · View post ↗“📈 5-year OS 64% with S-1 vs 52% with observation ⏱️ Median OS 8.2 vs 5.9 years - HR 0.72 (95% CI 0.55–0.95), one-sided p=.01”
— @DrAllanPereira · ASCOT trial 5-year results · View post ↗📌 Amplified by @KolPulseAI
“CD4 T cells convert transient responses to KRAS inhibition to durable remissions in #PancreaticCancer”
— @Aiims1742 · Preclinical KRAS inhibition research · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
The FDA has approved the combination of belzutifan and lenvatinib for patients with advanced clear cell renal cell carcinoma (ccRCC) following prior PD-1/PD-L1 inhibitor therapy. LITESPARK-011 compared the combination to cabozantinib and demonstrated an improved median progression-free survival of 14.6 months versus 10.6 months (HR 0.74), though the overall survival difference was not statistically significant.
“⚡️ FDA approves belzutifan + lenvatinib for advanced ccRCC after PD-1/PD-L1 inhibitor therapy. Based on LITESPARK-011: median PFS 14.6 vs 10.6 months (HR 0.74) vs cabozantinib. OS not significantly different at final analysis.”
— @drenriquegrande · Belzutifan + Lenvatinib Approval · View post ↗“Based off LITESPARK-011: Belzutifan + Lenvatinib is now @FDA ✅ in 2L RCC after IO exposure: PhIII: Bel + Len vs. Cabo - mPFS 14.6mos vs. 10.7mos (HR: 0.74) - mOS 33.7mos vs. 28.6mos (HR: 0.85, p=0.061). - AEs: 72% vs. 66% w/ Gr ≥ 3”
— @OncBrothers · LITESPARK-011 Data · View post ↗📌 Amplified by @KolPulseAI
“JUST IN: @FDA approves the combo of Lenvatinib+HIF2 inhibitor Belzutifan in advanced clear cell renal cell carcinoma following PD1/L1 inhibitor. Results based on Litespark-011 trial led by @motzermd @DrDanielHeng @SchmidigerManu1”
— @DrChoueiri · Belzutifan + Lenvatinib Approval · View post ↗
“New @FDA approval in advanced kidney cancer: belzutifan + lenvatinib after prior PD-1/PD-L1 therapy. Another meaningful option after IO.”
— @DrYukselUrun · Belzutifan + Lenvatinib Approval · View post ↗AbbVie's CERVINO plenary confirmed etentamig met both primary endpoints: ORR 74.0% vs 45.7% and PFS HR 0.40, with benefit consistent across prespecified subgroups. The investigational agent Ramantamig separately showed a strong 2-year PFS in a heavily pretreated, triple-class exposed population. A post-hoc analysis of the MajesTEC-3 trial was also discussed, with commentary suggesting real-world overall survival for teclistamab-daratumumab may exceed trial results due to improved supportive care. At IMS26, Dr. Nikhil Munshi proposed a new definition for a myeloma 'cure', requiring 5 years of sustained MRD negativity off all therapy plus negative imaging.
“The CERVINO trial met all primary endpoints: - ORR: 74.0% vs 45.7% - ≥CR: 40% vs 7% - PFS: HR 0.40 - 12-month PFS: 62.1% vs 28.4% The PFS benefit was consistent across prespecified subgroups. Impressive efficacy in a heavily pretreated population! 👏”
— @ptenfei · CERVINO Plenary Results · View post ↗
“Incredible 2-year PFS with Ramantamig in a ~95% CD38-refractory and 100% triple-class exposed population! These results are substantially superior compared to single-agent BCMA BsAbs and BCMA or GPRC5D CAR Ts in similar population.”
— @rajshekharucms · Ramantamig PFS Data · View post ↗📌 Amplified by @KolPulseAI
“Unlike other myeloma drugs, I bet real-world tec-dara OS will look *better* than MajesTEC-3 did. Why? Because we now know PPx toci, PPx IVIG, etc - early BsAb deaths can be prevented, vs fatal PD with Dara-Pd can't.”
— @RahulBanerjeeMD · MajesTEC-3 Real-World Outcomes · View post ↗📌 Amplified by @KolPulseAI
“When it comes to BsAbs (and now trispecific) T-cell engagers in myeloma, less is often more once response is obtained! Excellent to see ramantimig holding the #IMS26 line with Q8W dosing, i.e. only ~6x 💉 per year. Probably lower IVIG needs at this dose frequency as well!”
— @RahulBanerjeeMD · Bispecific Dosing Strategy · View post ↗📌 Amplified by @KolPulseAI
“#IMS26 Just read through @NEJM anito-cel paper. 🐘 in room is of course vs cilta-cel / CARTITUDE-1. I'm always guilty of cross-trial comparisons, but here even I would advise against it...”
— @RahulBanerjeeMD · Anito-cel Data · View post ↗📌 Amplified by @KolPulseAI
“Dr Holly Lee @hollyleeYJ presenting at #IMS23 updated data and novel mechanisms on TNFRSF17 mutations and resistance to anti-BCMA redirecting therapies”
— @NBahlis · BCMA Resistance Mechanisms · View post ↗A phase II study of investigational venetoclax plus a pediatric-inspired chemotherapy regimen for newly diagnosed Ph-negative acute lymphoblastic leukemia (ALL) in patients aged 14-60 showed a 91% complete remission rate and 78.5% 2-year overall survival. The hematology community is also reviewing practical ASTCT guidance on infection prevention after CAR-T therapy, covering prophylaxis for bacterial, fungal, and viral infections, as well as CMV surveillance and revaccination schedules.
“Promising phase II data for frontline venetoclax + pediatric-inspired chemotherapy in 167 pts age 14–60 with newly diagnosed Ph-negative ALL: CR 91%, post-induction MFC-MRD negativity 73% among responders, 2-year OS 78.5% and DFS 76.7%.”
— @TalhaBadarMD · Venetoclax in Ph-negative ALL · View post ↗📌 Amplified by @KolPulseAI
“🛡️ Infection prevention after CAR-T: practical ASTCT pearls 🧵”
— @abouabdrahman0 · CAR-T Infection Prevention · View post ↗